Cardiol Therapeutics Inc. CRDL.TO
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -1.21% | -8.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.95% | 22.83% | |||
| Operating Income | 18.95% | -22.83% | |||
| Income Before Tax | 44.28% | -52.44% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 44.28% | -52.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 44.28% | -52.44% | |||
| EBIT | 18.95% | -22.83% | |||
| EBITDA | 18.97% | -22.85% | |||
| EPS Basic | 47.24% | -37.12% | |||
| Normalized Basic EPS | 47.12% | -36.97% | |||
| EPS Diluted | 47.24% | -37.12% | |||
| Normalized Diluted EPS | 47.12% | -36.97% | |||
| Average Basic Shares Outstanding | 5.46% | 11.28% | |||
| Average Diluted Shares Outstanding | 5.46% | 11.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||